

Annual General Meeting of BioNTech SE on 25 May 2023

**Documents on Agenda Item 2: Proposal on the Appropriation of Balance Sheet Profit
for the 2021 Financial Year**

The Management Board proposes that the balance sheet profit of BioNTech SE from the 2021 financial year be appropriated as follows:

The balance sheet profit of BioNTech SE from the 2021 financial year of EUR 5,132,384,911.15 as reported in the annual financial statements as of 31 December 2021, of which a partial amount of EUR 484,202,456 has already been distributed to shareholders based on the resolution of the Annual General Meeting of 1 June 2022 and of which only a distributable amount of EUR 4,648,182,455.15 is thus disposable for the financial year 2021, as follows:

Balance sheet profit:	EUR 5,132,384,911.15
(of which already distributed to the shareholders:	EUR 484,202,456.00)
Distributable balance sheet profit:	EUR 4,648,182,455.15
Profit carried forward:	EUR 4,648,182,455.15

Mainz, March 2023

BioNTech SE

Management Board

Prof. Uğur Şahin, M.D.

Jens Holstein

Sean Marett

Dr. Sierk Poetting

Ryan Richardson

Prof. Özlem Türeci, M.D.